4//SEC Filing
Levine Mark S. 4
Accession 0001764013-24-000018
CIK 0001764013other
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 4:12 PM ET
Size
7.6 KB
Accession
0001764013-24-000018
Insider Transaction Report
Form 4
Immunovant, Inc.IMVT
Levine Mark S.
Chief Legal Officer
Transactions
- Sale
Common Stock
2024-01-26$37.91/sh−2,981$113,010→ 304,148 total - Sale
Common Stock
2024-01-26$38.45/sh−46$1,769→ 304,102 total
Footnotes (3)
- [F1]On January 28, 2022, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on January 31, 2022, of which 8,938 of these RSUs vested on January 19, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
- [F2]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.44 - $38.41 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.45 - $38.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
Documents
Issuer
Immunovant, Inc.
CIK 0001764013
Entity typeother
Related Parties
1- filerCIK 0001617236
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 4:12 PM ET
- Size
- 7.6 KB